Craig Eagle - 22 Oct 2026 Form 4 Insider Report for OS Therapies Inc (OSTX)

Reporting relationship: Director
Issuer ticker: OSTX
Reported as of: 22 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Oct 2026, 20:58:27 UTC
Prior SEC filing: 23 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Craig Eagle

Filing notes and source

Key filing fact

Craig Eagle filed Form 4 for OS Therapies Inc (OSTX) on 30 Oct 2026.

Key facts

This page summarizes Craig Eagle's Form 4 filing for OS Therapies Inc (OSTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Oct 2026, 20:58.

Change

Previous filing in this sequence was filed on 23 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001562135 Primary reporting owner

EAGLE CRAIG

Relationship: Director
Address: C/O OS THERAPIES INCORPORATED, 115 PULLMAN CROSSING ROAD, SUITE 103, GRASONVILLE
Signature: /s/ Craig Eagle
Signature date: 30 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OSTX transaction Derivative

Stock options (right to buy)

Award

Transaction value
Shares: +300,000
Change %
Price: $0.000000^*
Shares after: 300,000
Date: 22 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $1.25
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On October 22, 2026, the reporting person was granted options to purchase 300,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on each applicable vesting date.